TransMedics Group (NASDAQ:TMDX) Shares Up 11.9% – Still a Buy?

TransMedics Group, Inc. (NASDAQ:TMDX) traded up 11.9% during mid-day trading on Tuesday . The stock traded as high as $149.27 and last traded at $150.6250. 453,436 shares traded hands during trading, a decline of 17% from the average session volume of 549,156 shares. The stock had previously closed at $134.66.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on TMDX shares. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Zacks Research cut TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a research note on Sunday, December 28th. Morgan Stanley raised their price objective on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Finally, Jefferies Financial Group began coverage on TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 target price on the stock. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $144.25.

TransMedics Group Price Performance

The company’s 50-day simple moving average is $129.25 and its 200-day simple moving average is $122.21. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The stock has a market capitalization of $4.89 billion, a price-to-earnings ratio of 58.00 and a beta of 2.03.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.37 by $0.29. The company had revenue of $143.82 million for the quarter, compared to the consensus estimate of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The firm’s revenue for the quarter was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.12 earnings per share. Research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the transaction, the chief financial officer owned 15,064 shares in the company, valued at $2,103,235.68. This trade represents a 5.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Basile sold 4,142 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total transaction of $540,323.90. Following the completion of the sale, the director directly owned 2,866 shares of the company’s stock, valued at approximately $373,869.70. The trade was a 59.10% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 13,062 shares of company stock valued at $1,797,634. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors have recently made changes to their positions in the stock. Opal Wealth Advisors LLC bought a new position in TransMedics Group during the 2nd quarter worth $26,000. Whittier Trust Co. of Nevada Inc. increased its position in shares of TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares during the period. Salomon & Ludwin LLC bought a new position in shares of TransMedics Group in the third quarter worth $28,000. Harvest Fund Management Co. Ltd acquired a new position in TransMedics Group in the third quarter valued at about $29,000. Finally, Optiver Holding B.V. lifted its position in TransMedics Group by 248.1% during the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after purchasing an additional 191 shares during the period. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.